Amyloid precursor protein (APP) May act as a substrate and a recognition unit for CRL4CRBN and Stub1 E3 ligases facilitating ubiquitination of proteins involved in presynaptic functions and neurodegeneration
Open accessAbstract
The amyloid precursor protein (APP), whose mutations cause Alzheimer disease, plays an important in vivo role and facilitates transmitter release. Because the APP cytosolic region (ACR) is essential for these functions, we have characterized its brain interactome. We found that the ACR interacts with proteins that regulate the ubiquitin-proteasome system, predominantly with the E3 ubiquitin-protein ligases Stub1, which binds the NH2 terminus of the ACR, and CRL4(CRBN), which is formed by Cul4a/b, Ddb1, and Crbn, and interacts with the COOH terminus of the ACR via Crbn. APP shares essential functions with APP-like protein-2 (APLP2) but not APP-like protein-1 (APLP1). Noteworthy, APLP2, but not APLP1, interacts with Stub1 and CRL4(CRBN), pointing to a functional pathway shared only by APP and APLP2. In vitro ubiquitination/ubiquitome analysis indicates that these E3 ligases are enzymatically active and ubiquitinate the ACR residues Lys(649/650/651/676/688) Deletion of Crbn reduces ubiquitination of Lys(676) suggesting that Lys(676) is physiologically ubiquitinated by CRL4(CRBN) The ACR facilitated in vitro ubiquitination of presynaptic proteins that regulate exocytosis, suggesting a mechanism by which APP tunes transmitter release. Other dementia-related proteins, namely Tau and apoE, interact with and are ubiquitinated via the ACR in vitro This, and the evidence that CRBN and CUL4B are linked to intellectual disability, prompts us to hypothesize a pathogenic mechanism, in which APP acts as a modulator of E3 ubiquitin-protein ligase(s), shared by distinct neuronal disorders. The well described accumulation of ubiquitinated protein inclusions in neurodegenerative diseases and the link between the ubiquitin-proteasome system and neurodegeneration make this concept plausible.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Some basal interaction between tau and CRL4CRBN E3 ligase may occur endogenously in human neurons.
“suggesting that some basal interaction between tau and the CRL4CRBN E3 ligase may also occur endogenously in human neurons, as has been reported in tissue from mouse brain”
From Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models (2019) · cites this paper as Del Prete et al., 2016
Tau could be a natural substrate of CRBN through a complex involving the amyloid precursor protein (APP), mutations in which are known to cause AD.
“Del Prete et al. reported that tau could be a natural substrate of CRBN through a complex involving the amyloid precursor protein (APP), mutations in which are known to cause AD (Del Prete et al., 2016).”
From Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models (2019) · cites this paper as Del Prete et al., 2016
The citation lists haven’t been fetched yet
References 144 · Cited by 86
- Authors
- Del Prete, D., Rice, R. C., Rajadhyaksha, A. M., & D'Adamio, L.
- Affiliations
- Cornell University (US)
- Albert Einstein College of Medicine (US)
- Corresponding author
- D'Adamio, Luciano
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 291
- Issue
- 33
- Pages
- 17209-17227
- ISSN
- 0021-9258 (ISSN-L)
- PMC
- PMC5016122
- OpenAlex
- W2428905495
- Semantic Scholar
- 85c3538e120a1022eb4ba43a03c11e8323e28568
- Cited by
- 86
- References
- 144
- Citations by year
- 2026: 11 · 2025: 5 · 2024: 4 · 2023: 6 · 2022: 16 · 2021: 9 · 2020: 9 · 2019: 11 · 2018: 10 · 2017: 4 · 2016: 1
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (R01AG033007, R01AG041531, R21AG048971, R01AG052286)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- amyloid precursor protein, STUB1, E3 ubiquitin ligase, ubiquitination, ubiquitin-proteasome system, presynaptic proteins, neurotransmitter release, exocytosis, APLP2, APLP1, tau protein, apolipoprotein E, neurodegeneration, Alzheimer's disease, intellectual disability, CUL4B, protein-protein interaction network
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, DNA-Binding Proteins, Humans, Multienzyme Complexes, Nerve Tissue Proteins, Synaptic Transmission, Amyloid beta-Protein Precursor, tau Proteins, Ubiquitin-Protein Ligases, Cullin Proteins, Adaptor Proteins, Signal Transducing, Mice, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review